Evidence map›Paper›PMID 41399780›Full record

ArticleMolecular therapy. Oncology2025

Efficacy and safety of BRAF-MEK inhibitors in treatment of Chinese patients with papillary craniopharyngioma: A retrospective cohort study.

Rui Han, Xiaorong Yan, Boyuan Yao, Boyu Cai, Nidan Qiao, Zengyi Ma, Zhen Ye, Xufang Gu, Zhao Ye, Buqing Liang and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rui HanDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Xiaorong YanDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China.
Boyuan YaoDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Boyu CaiDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Nidan QiaoDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Zengyi MaDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Zhen YeDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Xufang GuDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Zhao YeDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Buqing LiangDepartment of Neurosurgery, Loma Linda University Health, Loma Linda, CA 92354, USA.
Zhengyuan ChenDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Wenqiang HeDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Yifei YuDepartment of Endocrine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Xiaoyun CaoDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Haixia ChengDepartment of Pathology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Hong ChenDepartment of Pathology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Yongfei WangDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Hongying YeDepartment of Endocrine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Zhaoyun ZhangDepartment of Endocrine, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Yao ZhaoState Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai 200032, China.
Ruofan HuangDepartment of Oncology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.
Qilin ZhangDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai 200040, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous research supports the efficacy of BRAF-MEK inhibitor therapy for papillary craniopharyngiomas (PCPs). This retrospective study of 30 Chinese PCP patients evaluated tumor response and safety outcomes during treatment. All patients maintained 100% progression-free and overall survival throughout the follow-up. Tumor measurements revealed consistent reductions over time, with maximum diameter decreasing by 45.81% (31.01%-66.67%) at 1 month, 56.26% (46.67%-66.67%) at 3 months, and 59.50% (46.84%-69.94%) at the final follow-up. Similar patterns emerged for both solid and cystic components. Notably, neoadjuvant therapy demonstrated superior efficacy (60.35% reduction) compared to adjuvant approaches (42.90% reduction) at 1 month, particularly for solid tumor portions. Adverse events occurred more frequently during the initial 3-month period. These findings highlight the clinical value of BRAF-MEK inhibitor combinations for PCP treatment while suggesting potential limitations of extended targeted therapy duration.

Indexed as

BRAF-MEK inhibitorsefficacyMT: Regular Issuenature historypapillary craniopharyngiomasPCPssafety

Identifiers

PMID41399780
PMCPMC12701989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.